OAB-001: Overall survival and progression-free survival by treatment duration with Daratumumab + Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study
Titel:
OAB-001: Overall survival and progression-free survival by treatment duration with Daratumumab + Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study
Auteur:
Moreau, Philippe Facon, Thierry Kumar, Shaji Plesner, Torben Orlowski, Robert Z. Bahlis, Nizar Basu, Supratik Nahi, Hareth Hulin, Cyrille Quach, Hang Goldschmidt, Hartmut O’Dwyer, Michael Perrot, Aurore Venner, Christopher Weisel, Katja Mace, Joseph R. Raje, Noopur Tiab, Mourad Macro, Margaret Frenzel, Laurent Leleu, Xavier Pei, Huiling Tromp, Brenda Delioukina, Maria Usmani, Saad Z.